ReNeuron reaches exosome research milestone
4th Sep 2023 11:10
(Sharecast News) - UK-based biotechnology company ReNeuron Group, which specialises in stem cell-derived exosome technologies, announced significant advancements in the field of exosome research on Monday.
Read moreDirector dealings: Reneuron CFO makes share purchase
24th Jan 2023 14:44
(Sharecast News) - Reneuron revealed on Tuesday that chief financial officer John Hawkins had acquired 100,000 ordinary shares in the AIM-listed stem cell technologies group.
Read moreReNeuron shares tumble after first-half results
2nd Dec 2022 12:47
(Sharecast News) - Stem-cell-derived exosome technology specialist ReNeuron Group reported first-half revenue of £0.44m on Friday, up from £0.06m year-on-year, related to income from partner-funded development activities and royalty income.
Read moreReNeuron enters cancer therapy collaboration with UCL
26th Oct 2021 14:02
(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.
Read moreDirector dealings: Reneuron Group non-executive makes share purchase
21st Oct 2021 16:40
(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.
Read moreReNeuron treats first Oxford patient as part of expanded study
18th Oct 2021 09:14
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.
Read moreReNeuron upbeat on positive data from Spain collaboration
11th Oct 2021 11:51
(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.
Read moreReNeuron gets approval to restart RP clinical study
1st Oct 2021 10:33
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.
Read moreReNeuron signs new collaboration agreements
19th Mar 2021 16:43
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the signing of new collaboration agreements with a major pharmaceutical company and leading academic institutions in the UK and mainland Europe on Friday.
Read moreReNeuron gets patent allowance in the US
31st Jul 2020 16:22
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Friday that the US Patent and Trademark office (USPTO) has completed its examination of its application titled 'phenotype profile of human retinal progenitor cells', and has issued a notification of allowance for the issue of a patent.
Read moreReNeuron Group inks research evaluation deal with US firm
25th Jun 2020 11:22
(Sharecast News) - Cell-based therapeutics company ReNeuron Group announced on Thursday that it has signed a new research evaluation agreement with a major United States biotechnology company, in connection with the use of its proprietary exosomes for the delivery of novel gene silencing therapeutics.
Read moreReNeuron cuts losses after Fosun licence payment
6th Dec 2019 10:42
(Sharecast News) - ReNeuron Group on Friday reported a narrower interim loss after receiving payment from a Chinese licensee, while it also made progress in its clinical and research programmes.
Read moreReNeuron presents new data on CTX stem cell platform
23rd Oct 2019 15:50
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.
Read moreReNeuron boosts scientific advisory board with three appointments
21st Aug 2019 11:49
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.
Read moreReNeuron enters grant-funded partnership with University of Cardiff
14th Aug 2019 11:16
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.
Read more